Neuroscience INSIGHTS


New Neurons

On August 27, 2018, researchers at University of Szeged, Allen Institute for Brain Science, J. Craig Venter Institute, Hungarian Academy of Sciences, Illumina, Inc., and University of California, San Diego published a paper titled, Transcriptomic and morphophysiological evidence for a specialized human cortical GABAergic cell type in the journal Nature Neuroscience. The research was featured on NPR and looks at newly discovered neurons named "rose hip neurons"...

Read More

PD-1 Blockade Ineffective in AD Mouse Models

More than 45 million people worldwide suffer from Alzheimer's disease (AD) or dementia. The costs are staggering, and no cure exists. Development of new therapies has been challenging, with many promising new drugs failing in late stage clinical trials. Inducing Immune Response in AD Mouse Models Interest in new therapeutic pathways was piqued in 2016, when Baruch et al. reported that PD-1 checkpoint inhibition induced an immune...

Read More

The Long-Term Impacts of Traumatic Brain Injury

National Vital Statistics System Mortality Data — United States, 2001-2010 (Deaths) Traumatic brain injury (TBI) is a growing problem. An estimated 10 million people are affected annually worldwide by TBI, and the burden of mortality and morbidity that imposes on society makes TBI a pressing public health and medical problem1. The populations most at risk are children, teens, and the elderly and TBI contributes to numerous hospital...

Read More

World MS Day

To mark World MS Day and raise awareness of this disease, we're taking a look at the state of preclinical MS research and efforts to produce more translatable MS animal models. What is Multiple Sclerosis? Multiple sclerosis (MS) is a progressive disease of the nervous system, one of the most common neurological disorders and causes of disability in young adults. MS affects 2.3 million people worldwide, including...

Read More

Tauopathy Alzheimer's Disease Models Yield Contrasting Results

In a recent Alzheimer's Research and Therapy article, scientists described failing to elicit beneficial effects from a tau-directed antibody therapy while evaluating its efficacy in the Tg4510 mouse, an Alzheimer's disease (AD) model with a tamoxifen-controlled transgene expressing P301L mutant tau. The results contrast prior successes reported with the antibody therapy the researchers were testing. The therapeutic, a tau oligomer-specific monoclonal antibody (TOMA), was reported to rescue...

Read More

National Drug and Alcohol Facts Week

During the third week of January The National Institute on Drug Abuse (NIDA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) host an annual event focusing on substance abuse and its impact on teenagers. Launched in 2010, the National Drug Alcohol Facts Week (NDAFW) focuses on substance abuse education, linking students with scientists and other experts to counteract the myths about drugs and alcohol. NDAFW is...

Read More

A Redox Link between APOE4 and Alzheimer's Disease Risk?

A Redox Link between APOE4 and Alzheimer's Disease Risk? Individuals homozygous for APOE4, one of three common genetic variants encoding Apolipoprotein E (apoE), carry approximately twelve-times higher risk for an Alzheimer's disease (AD) diagnosis. A recent study suggests a potentially critical link between apoE4 and the antioxidant enzyme Thioredoxin-1 (Trx1) may underlie enhanced AD risk in APOE4 carriers. APOE Alleles Modify Alzheimer's Risk ApoE protein is predominantly...

Read More

Chronic Pain Management Research and the Opioid Crisis

Developing novel drugs for chronic pain management — both more effective and less addictive than opioids — will reduce the number of patients at risk of opioid dependence. Chronic Pain and the Opioid Crisis More than 25% of Americans suffer from chronic pain. This is on par with adults from equivalent regions; between 10-25% of adults in other western countries experience chronic pain, while some estimates of...

Read More

Alzheimer's Requires Aggressive Funding — and Better Models

More than 5.5 million Americans are living with Alzheimer's disease (AD), the sixth leading cause of death among adults in the US. Aggressive research funding and improved animal models of Alzheimer's disease are urgent priorities. Increasing Alzheimer's Research Funding On July 19, 2017, the House Appropriations Committee approved an additional $400 million for Alzheimer's disease research in the fiscal year 2018 budget. $400 million was also approved...

Read More

Parkinson's Disease Model with Endogenous LRRK2 Regulation

No single Parkinson's Disease (PD) model fully reproduces the complexity of the disease in humans. Developing an assortment of PD models has been essential for furthering our understanding of, and the development of potential treatments for, the disease. Adding to the arsenal of PD rodent models, in conjunction with The Michael J. Fox Foundation (MJFF) for Parkinson's Research, a mouse model carrying targeted replacement human LRRK2 G2019S...

Read More